The Sagol Center for Hyperbaric Medicine and Research, Shamir Medical Center, Zerifin, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
BMC Pulm Med. 2019 Aug 13;19(1):148. doi: 10.1186/s12890-019-0893-8.
Oxygen toxicity is one potential side effect of hyperbaric oxygen therapy (HBOT). Previous small studies showed mild reductions in pulmonary functions reflecting reductions in small airway conductance after repetitive hyperbaric oxygen sessions. However, there are no updated data with well performed pulmonary tests that address the pulmonary effect of the currently used HBOT protocols. The aim of this study was to evaluate the effect of HBOT on pulmonary functions of patients receiving the currently used HBOT protocol.
Prospective analysis included patients, 18 years or older, scheduled for 60 daily HBOT sessions between 2016 and 2018. Each session was 90 min of 100% oxygen at 2 ATA with 5 min air breaks every 20 min, 5 days per week. Pulmonary functions, measured at baseline and after HBOT, included forced vital capacity (FVC), forced expiratory volume in 1 sec (FEV1) and peak expiratory flow rate (PEF).
The mean age was 60.36 ± 15.43 and 62.5% (55/88) were males. Most of the patients (83/88, 94.3%) did not have any pulmonary disease prior to inclusion and 30.7% (27/88) had a history of smoking. Compared to baseline values, at the completion of 60 HBOT sessions, there were no significant changes in FEV1 (0.163), FEV1/FVC ratio (0.953) and FEF25-75% (0.423). There was a statistically significant increase though not clinically relevant increase in FVC (0.1 ± 0.38 l) and PEF (0.5 ± 1.4 l) with a 0.014 and 0.001 respectively.
Regarding pulmonary functions, repeated hyperbaric oxygen exposure based on the currently used HBOT protocol is safe. Surprisingly, there was a modest non clinically significant though statistically significant improvement in PEF and FVC in the current cohort of patients who were without chronic lung diseases.
Clinicaltrials.gov, trial ID: NCT03754985 , (Nov 2018) Retrospectively registered.
高压氧治疗（HBOT）的一个潜在副作用是氧中毒。先前的小样本研究表明，在重复高压氧治疗后，肺功能会出现轻微下降，反映出小气道传导能力下降。然而，目前还没有更新的数据，也没有经过良好设计的肺功能测试来评估当前使用的 HBOT 方案对肺部的影响。本研究的目的是评估当前使用的 HBOT 方案对接受 HBOT 的患者的肺功能的影响。
前瞻性分析纳入了 2016 年至 2018 年期间接受 60 次每日 HBOT 治疗的年龄在 18 岁或以上的患者。每次治疗持续 90 分钟，氧气浓度为 100%，压力为 2ATA，每 20 分钟休息 5 分钟空气，每周 5 天。治疗前后测量的肺功能包括用力肺活量（FVC）、1 秒用力呼气量（FEV1）和呼气峰流速（PEF）。
患者的平均年龄为 60.36±15.43 岁，62.5%（55/88）为男性。大多数患者（83/88，94.3%）在纳入前没有任何肺部疾病，30.7%（27/88）有吸烟史。与基线值相比，在完成 60 次 HBOT 治疗后，FEV1（0.163）、FEV1/FVC 比值（0.953）和 FEF25-75%（0.423）没有显著变化。尽管没有临床意义，但 FVC（0.1±0.38l）和 PEF（0.5±1.4l）均有统计学显著增加，分别为 0.014 和 0.001。
就肺功能而言，基于当前使用的 HBOT 方案的重复高压氧暴露是安全的。令人惊讶的是，在当前无慢性肺部疾病的患者队列中，PEF 和 FVC 出现了适度的非临床显著但具有统计学意义的改善。
Clinicaltrials.gov，试验 ID：NCT03754985，（2018 年 11 月）回顾性注册。
